

Full Year 2020 Results

2020 Sales

Worldwide Increased ▲
\$82.6B | **0.6%**

Excluding acquisitions/
 divestitures on an
 operational basis | Worldwide Increased ▲
1.5%*

Diluted Earnings Per Share

Decreased ▼
\$5.51 | **(2.1)%**

Adjusted Diluted Earnings Per Share*

Decreased ▼
\$8.03 | **(7.5)%**



Alex Gorsky
 Chairman and
 Chief Executive Officer
 Johnson & Johnson

“Our notable full year performance reflects the continued confidence from patients, physicians, customers and consumers in our life-enhancing products and medicines, particularly throughout the COVID-19 pandemic. I’m incredibly proud of our Johnson & Johnson teams around the world for going above and beyond to meet stakeholder needs. These efforts, and our commitment to families around the world as the largest broad-based healthcare company, enabled us to lead in the fight against COVID-19. We continue to progress our COVID-19 vaccine candidate and look forward to sharing details from our Phase 3 study soon. Johnson & Johnson was built for times like these, and I am extremely confident in our ability to deliver lasting value and continued innovation in 2021 and for years to come.”

**\$14.1
 Billion**

Worldwide Consumer Health Sales


Consumer Health worldwide reported sales increased 1.1% or 3.0% operationally¹. Primary operational drivers:



**\$45.6
 Billion**

Worldwide Pharmaceutical Sales


Pharmaceutical worldwide reported sales increased 8.0% or 8.2% operationally¹. Primary operational drivers:



**\$23.0
 Billion**

Worldwide Medical Devices Sales

Medical Devices worldwide reported sales decreased (11.6)% or (11.4)% operationally¹. Offsets to decline:



Note: values may have been rounded

For full financial data and non-GAAP reconciliations, please refer to Johnson & Johnson's earnings release issued on January 26, 2021, available at <http://www.investor.jnj.com/sales-earnings.cfm>.

*Non-GAAP financial measure; non-GAAP financial measures should not be considered replacements for, and should be read together with, the most comparable GAAP financial measures.

¹Non-GAAP measure; excludes the impact of translational currency.

Caution Concerning Forward-Looking Statements: This document contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 regarding future operating and financial performance. You are cautioned not to rely on these forward-looking statements, which are based on current expectations of future events. For important information about the risks and uncertainties that could cause actual results to vary materially from the assumptions, expectations, and projections expressed in any forward-looking statements, review the “Note to Investors Concerning Forward-Looking Statements” included in the Johnson & Johnson earnings release issued on January 26, 2021, as well as the most recently filed Johnson & Johnson Reports on Forms 10-K and 10-Q. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments.